News

According to TipRanks.com, Richter is a 4-star analyst with an average return of 8.8% and a 42.9% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx ...
The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...
With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...
The Trump Administration said this week it is pulling half a billion dollars from U.S. government-funded research projects to create new mRNA vaccines. Experts say this could potentially impact mRNA ...
In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...
The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...
A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and ...